Bilix

2:00 PM - 2:15 PM (EDT), Tuesday, October 22, 2019 ・ 2nd Floor
Bilix is a newly founded biotech company that specializes in developing new drugs for intractable diseases in inflammation and cancer. Its main technology has been developed by Endowed Professor at KAIST (Korean Advanced Institute of Science and Technology) for the past 7 years from which 3 patent applications have been transferred to Bilix.
Bilirubin has been known to be a strong anti-oxidant and an effective immune modulator. Although its clinical implications and efficacies have been known and proved by hundreds of publications, it has never been developed into a clinical trials due to its strong toxicity arising from hydrophobicity. Bilix has developed a platform technology to improve efficacy and yet remove toxicity. Its efficacy has been tested and published in 7 different disease animal models (myocardial ischemic reperfusion injury, inflammatory bowl disease, GvHD, Asthama, organ transplant, etc) for $50 B + market. We are at stage of manufacturing for pre-clinical studies.
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
2018
Main Therapeutic Focus:
Lead Product in Development:
OPTA-Infla
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Over 20